Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 Trial.
(2010) In Journal of Clinical Oncology Jul 1. p.3284-3291- Abstract
- PURPOSE To improve the poor prognosis of patients with primary disseminated multifocal Ewing sarcomas (PDMES) with a dose-intense treatment concept. PATIENTS AND METHODS From 1999 to 2005, 281 patients with PDMES were enrolled onto the Euro-EWING 99 R3 study. Median age was 16.2 years (range, 0.4 to 49 years). Recommended treatment consisted of six cycles of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE), one cycle of vincristine, dactinomycin, and ifosfamide (VAI), local treatment (surgery and/or radiotherapy), and high-dose busulfan-melphalan followed by autologous stem-cell transplantation (HDT/SCT). Results After a median follow-up of 3.8 years, event-free survival (EFS) and overall survival (OS) at 3 years for all 281... (More)
- PURPOSE To improve the poor prognosis of patients with primary disseminated multifocal Ewing sarcomas (PDMES) with a dose-intense treatment concept. PATIENTS AND METHODS From 1999 to 2005, 281 patients with PDMES were enrolled onto the Euro-EWING 99 R3 study. Median age was 16.2 years (range, 0.4 to 49 years). Recommended treatment consisted of six cycles of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE), one cycle of vincristine, dactinomycin, and ifosfamide (VAI), local treatment (surgery and/or radiotherapy), and high-dose busulfan-melphalan followed by autologous stem-cell transplantation (HDT/SCT). Results After a median follow-up of 3.8 years, event-free survival (EFS) and overall survival (OS) at 3 years for all 281 patients were 27% +/- 3% and 34% +/- 4% respectively. Six VIDE cycles were completed by 250 patients (89%); 169 patients (60%) received HDT/SCT. The estimated 3-year EFS from the start of HDT/SCT was 45% for 46 children younger than 14 years. Cox regression analyses demonstrated increased risk at diagnosis for patients older than 14 years (hazard ratio [HR] = 1.6), a primary tumor volume more than 200 mL (HR = 1.8), more than one bone metastatic site (HR = 2.0), bone marrow metastases (HR = 1.6), and additional lung metastases (HR = 1.5). An up-front risk score based on these HR factors identified three groups with EFS rates of 50% for score </= 3 (82 patients), 25% for score more than 3 to less than 5 (102 patients), and 10% for score >/= 5 (70 patients; P < .0001). CONCLUSION PDMES patients may survive with intensive multimodal therapy. Age, tumor volume, and extent of metastatic spread are relevant risk factors. A score based on these factors may facilitate risk-adapted treatment approaches. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1626058
- author
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Clinical Oncology
- volume
- Jul 1
- pages
- 3284 - 3291
- publisher
- American Society of Clinical Oncology
- external identifiers
-
- wos:000279637600014
- pmid:20547982
- scopus:77954727583
- pmid:20547982
- ISSN
- 1527-7755
- DOI
- 10.1200/JCO.2009.22.9864
- language
- English
- LU publication?
- yes
- id
- 2c805fbc-6fde-4d1f-b51d-16e28f7ccc74 (old id 1626058)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/20547982?dopt=Abstract
- date added to LUP
- 2016-04-04 08:47:54
- date last changed
- 2022-04-23 17:43:13
@article{2c805fbc-6fde-4d1f-b51d-16e28f7ccc74,
abstract = {{PURPOSE To improve the poor prognosis of patients with primary disseminated multifocal Ewing sarcomas (PDMES) with a dose-intense treatment concept. PATIENTS AND METHODS From 1999 to 2005, 281 patients with PDMES were enrolled onto the Euro-EWING 99 R3 study. Median age was 16.2 years (range, 0.4 to 49 years). Recommended treatment consisted of six cycles of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE), one cycle of vincristine, dactinomycin, and ifosfamide (VAI), local treatment (surgery and/or radiotherapy), and high-dose busulfan-melphalan followed by autologous stem-cell transplantation (HDT/SCT). Results After a median follow-up of 3.8 years, event-free survival (EFS) and overall survival (OS) at 3 years for all 281 patients were 27% +/- 3% and 34% +/- 4% respectively. Six VIDE cycles were completed by 250 patients (89%); 169 patients (60%) received HDT/SCT. The estimated 3-year EFS from the start of HDT/SCT was 45% for 46 children younger than 14 years. Cox regression analyses demonstrated increased risk at diagnosis for patients older than 14 years (hazard ratio [HR] = 1.6), a primary tumor volume more than 200 mL (HR = 1.8), more than one bone metastatic site (HR = 2.0), bone marrow metastases (HR = 1.6), and additional lung metastases (HR = 1.5). An up-front risk score based on these HR factors identified three groups with EFS rates of 50% for score </= 3 (82 patients), 25% for score more than 3 to less than 5 (102 patients), and 10% for score >/= 5 (70 patients; P < .0001). CONCLUSION PDMES patients may survive with intensive multimodal therapy. Age, tumor volume, and extent of metastatic spread are relevant risk factors. A score based on these factors may facilitate risk-adapted treatment approaches.}},
author = {{Ladenstein, Ruth and Pötschger, Ulrike and Le Deley, Marie Cécile and Whelan, Jeremy and Paulussen, Michael and Oberlin, Odile and van den Berg, Henk and Dirksen, Uta and Hjorth, Lars and Michon, Jean and Lewis, Ian and Craft, Alan and Jürgens, Heribert}},
issn = {{1527-7755}},
language = {{eng}},
pages = {{3284--3291}},
publisher = {{American Society of Clinical Oncology}},
series = {{Journal of Clinical Oncology}},
title = {{Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 Trial.}},
url = {{http://dx.doi.org/10.1200/JCO.2009.22.9864}},
doi = {{10.1200/JCO.2009.22.9864}},
volume = {{Jul 1}},
year = {{2010}},
}